Phase 4
N=71
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Migraine
Bottom Line
View on ClinicalTrials.gov: NCT00259649 ↗Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- eletriptan (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Pittsburgh
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Headache Index Score Among Patients |
-1.52 | — |
Summary
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.
Eligibility Criteria
Inclusion Criteria
- age 18-45 healthy menstruating female
Exclusion Criteria
- cardiac or other conditions precluding use of eletriptan
Data sourced from ClinicalTrials.gov (NCT00259649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.